Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Lung Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Mouth Neoplasms 2Liver Neoplasms 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2von Hippel-Lindau Disease 1Vaginal Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2atezolizumab 1X-Rays 1Tiragolumab 1Phantoms, Imaging 1Nivolumab 1Ipilimumab 1Gelclair 1Fluorodeoxyglucose F18 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Chordoma × Fluorodeoxyglucose F18 × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡